2026-09-20T10:39:13Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/448402022-01-13T07:54:37Zcom_1721.1_7582com_1721.1_7581col_1721.1_131024
Anna-Liisa Brownell and David Cory.
Lamb, Peter (Peter Alexander John)
Massachusetts Institute of Technology. Dept. of Nuclear Science and Engineering.
Massachusetts Institute of Technology. Department of Nuclear Science and Engineering
2009-03-16T19:49:37Z
2009-03-16T19:49:37Z
2008
2008
http://hdl.handle.net/1721.1/44840
301587846
Thesis (S.B.)--Massachusetts Institute of Technology, Dept. of Nuclear Science and Engineering, 2008.
Includes bibliographical references (leaves 26-27).
MicroPET imaging studies were conducted to investigate the role of metabotropic glutamate subtype-5 receptors (mGluR5) in Parkinson's disease (PD). Four analogical PET ligands were used to characterize modulation of mGluR5 function in a 6hydroxydopamine (6-OHDA) induced rat model of PD. Unilateral 6-OHDA lesions were made in the right medial forebrain bundle, and severity of these lesions was determined with [¹¹]CFT. The binding characteristics of the PET ligands were analyzed using a modified distribution volume method of the Logan reference region model. Binding potential values were calculated on the striatum, hippocampus, and cortex, using the cerebellum as a reference tissue. On the right (with lesion) side of the striatum, ["C]CFT binding decreased. Three of the four investigated mGluR5 ligands ([¹¹C]MPEP, [¹¹C]M-PEPy, and [¹¹C]MMPEP) also showed enhanced binding characteristics on the same side of the brain. The right hippocampus and cortex showed similar results. The mGluR5s' enhanced binding characteristics on the right side of the brain suggest a complementary and compensatory role of metabotropic glutamate receptors in the dopaminergic neurodegeneration of Parkinson's disease.
by Peter Lamb.
S.B.
27 leaves
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by
copyright. They may be viewed from this source for any purpose, but
reproduction or distribution in any format is prohibited without written
permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Nuclear Science and Engineering.
Characterizing the modulation of mGluR5 in a 6-OHDA-induced rat model of Parkinson's disease
Thesis
application/pdf
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="a0aa25ef-f716-4591-9522-21722099f39f">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Characterizing the modulation of mGluR5 in a 6-OHDA-induced rat model of Parkinson's disease</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2008</PublicationDate>
<Authors>
<Author>
<DisplayName>Lamb, Peter (Peter Alexander John)</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Nuclear Science and Engineering.</Keyword>
<Abstract>MicroPET imaging studies were conducted to investigate the role of metabotropic glutamate subtype-5 receptors (mGluR5) in Parkinson's disease (PD). Four analogical PET ligands were used to characterize modulation of mGluR5 function in a 6hydroxydopamine (6-OHDA) induced rat model of PD. Unilateral 6-OHDA lesions were made in the right medial forebrain bundle, and severity of these lesions was determined with [¹¹]CFT. The binding characteristics of the PET ligands were analyzed using a modified distribution volume method of the Logan reference region model. Binding potential values were calculated on the striatum, hippocampus, and cortex, using the cerebellum as a reference tissue. On the right (with lesion) side of the striatum, ["C]CFT binding decreased. Three of the four investigated mGluR5 ligands ([¹¹C]MPEP, [¹¹C]M-PEPy, and [¹¹C]MMPEP) also showed enhanced binding characteristics on the same side of the brain. The right hippocampus and cortex showed similar results. The mGluR5s' enhanced binding characteristics on the right side of the brain suggest a complementary and compensatory role of metabotropic glutamate receptors in the dopaminergic neurodegeneration of Parkinson's disease.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>